Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years.

Heini, Alexander D; Berger, Martin Dave; Seipel, Katja; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Leibundgut, Kurt; Banz Wälti, Yara; Novak, Urban; Pabst, Thomas (2017). Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years. Leukemia research, 53, pp. 28-34. Elsevier 10.1016/j.leukres.2016.12.001

[img] Text
1-s2.0-S0145212616302636-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy
[img]
Preview
Text
1-s2.0-S0145212616302636-main.pdf - Published Version
Available under License Publisher holds Copyright.

Download (1MB) | Preview

The outcome of AML patients ≥65 years remains disappointing. Current post-induction strategies for elderly AML patients fit for intensive treatment involve additional cycles of chemotherapy or allogeneic transplantation. Consolidation with autologous transplantation (ASCT) is poorly studied in these patients. In this single-center retrospective analysis, we determined survival rates of AML patients ≥65 years undergoing busulfan/cyclophosphamide conditioning before ASCT in first remission between 2007 and 2015. We found elderly AML patients with ASCT to have longer progression-free survival (PFS; 16.3 vs. 5.1 months, P=0.0166) and overall survival (OS; n.r. vs. 8.2 months; P=0.0255) than elderly AML patients without ASCT consolidation. In addition, elderly AML patients undergoing ASCT had comparable PFS (P=0.9462) and OS (P=0.7867) as AML patients below 65 years receiving ASCT consolidation in CR1. Our data suggest that ASCT is an option in elderly fit AML patients who appear to benefit from autologous consolidation similarly to younger AML patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Berger, Martin Dave; Seipel, Katja; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Leibundgut, Kurt; Banz Wälti, Yara; Novak, Urban and Pabst, Thomas

Subjects:

600 Technology > 610 Medicine & health
500 Science > 570 Life sciences; biology

ISSN:

0145-2126

Publisher:

Elsevier

Language:

English

Submitter:

Marianne Zahn

Date Deposited:

23 Dec 2016 13:51

Last Modified:

12 Feb 2018 16:01

Publisher DOI:

10.1016/j.leukres.2016.12.001

PubMed ID:

27978458

Uncontrolled Keywords:

AML; Autologous; Elderly; Survival; Transplant

BORIS DOI:

10.7892/boris.92000

URI:

https://boris.unibe.ch/id/eprint/92000

Actions (login required)

Edit item Edit item
Provide Feedback